

Received Date : 26-Jun-2016

Revised Date : 28-Jul-2016

Accepted Date : 07-Oct-2016

Article type : Original Article

## **Center is an important indicator for choice of invasive therapy in polycystic liver disease**

Hedwig M.A. D'Agnolo<sup>1</sup>, MD; Wietske Kievit<sup>2</sup>, PhD; Kim N. van Munster<sup>1</sup>, MD; Jouke J.H. vd Laan<sup>1</sup>, BSc; Frederik Nevens<sup>3</sup>, MD, PhD; Joost P.H. Drenth<sup>1</sup>MD, PhD

<sup>1</sup> *Department of Gastroenterology and Hepatology, Radboud university medical center Nijmegen, the Netherlands*

<sup>2</sup> *Radboud Institute for Health Sciences, Radboud university medical center Nijmegen, the Netherlands*

<sup>3</sup> *Department of Gastroenterology and Hepatology, University Hospital Leuven, Belgium*

### **Corresponding author:**

Hedwig M.A., MD

Dept. Gastroenterology and Hepatology

Radboud University Medical Center Nijmegen

P.O. Box 9101

6500 HB Nijmegen

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/tri.12875

This article is protected by copyright. All rights reserved.

Phone: 0031 24 361 9190

Fax: 0031 24 354 0103

**E-mail:** hedwig.dagnolo@radboudumc.nl

**Meeting presentation:** The results of this study were presented at the International Liver Congress April 13-17, 2016 (EASL), Barcelona, Spain.

**Short title:** Invasive therapy for polycystic liver disease

**Conflict of interest:** no conflict of interests

**Financial support:** EASL Registry Research Grants Programme. EASL had no role in the design or conduct of the study, or in the writing and submission of the manuscript.

**Author's disclosure:** All authors have made substantive intellectual contributions to this manuscript and approved the final manuscript.

## **Abstract**

### **Background**

Polycystic liver disease (PLD) is a rare genetic disorder with progressive cyst growth as the primary phenotype. Therapy consists of volume reduction through invasive surgical or radiological procedures. In order to understand the process of treatment decision, our aim was to identify factors that increased the likelihood of treatment.

This article is protected by copyright. All rights reserved.

## Study Design

We performed a cross-sectional study using an international population of PLD patients. We collected data on the following therapies: liver transplantation, resection, fenestration and aspiration sclerotherapy. Data on the potential determinants: sex, center, autosomal dominant polycystic kidney disease (ADPKD), autosomal dominant polycystic liver disease (ADPLD), age at diagnosis, symptoms and phenotype were included. We corrected for follow-up time.

## Results

We included 578 patients in our study and 35% underwent invasive therapy. Multivariate regression analysis showed that number of symptoms) and age at diagnosis of PLD increased the likelihood of treatment (respectively RR 1.4,  $p<0.001$  and RR =1.4,  $p=0.03$ ). The choice for liver transplantation or aspiration sclerotherapy was center-dependent (RR 0.7,  $p<0.001$  and RR 1.1,  $p=0.03$  respectively).

## Conclusion

The results of our international cross-sectional study suggests that a higher number of symptoms and every 10 years of PLD diagnosis increases the risk to undergo treatment by 40%. The choice to elect a particular modality is center dependent.

**Keywords:** autosomal dominant polycystic kidney disease, autosomal dominant polycystic liver disease, polycystic liver disease, surgery, treatment

## Abbreviations

ADPKD	Autosomal dominant polycystic kidney disease
ADPLD	Autosomal dominant polycystic liver disease
hTLV	Height-adjusted total liver volume
PLD	Polycystic liver disease

RR	Risk ratio
TLV	Total liver volume

## Introduction

Polycystic liver disease (PLD) is a condition characterized by progressive liver cyst growth.

(1) PLD is part of the phenotype of two genetically distinct disorders. It is present as a primary phenotype in autosomal dominant polycystic liver disease (ADPLD), and it is the most common extra-renal manifestation in autosomal dominant polycystic kidney disease (ADPKD). (2-4) Isolated PLD is rare with a prevalence of 1 in 158.000, which contrasts that of ADPKD which has a higher prevalence (1: 400-1000 individuals). (5, 6) The vast majority of ADPKD patients (94%) > 35 years-of-age possess hepatic cysts. (4)

Although PLD is often asymptomatic, patients who progress to severe hepatomegaly have a decreased health-related quality of life and are often in need of therapy. (7, 8) Risk factors for progressive disease are age, female sex, estrogen use and pregnancies. (8-11) The concept central to PLD therapy is downsizing liver volume as this leads to improvement of symptoms. (3) Currently, the mainstay of therapies include invasive surgical and radiological procedures such as, liver transplantation, the only curative treatment, resection, fenestration and aspiration sclerotherapy.(2, 12) Treatment is indicated in patients who suffer from symptomatic hepatomegaly and the choice for a specific therapy mainly depends on the presence and location of dominant cysts. (2, 3, 13) Clear guidelines about timing and choice of therapy are lacking. This might be explained by a lack of evidence generated by clinical trials comparing efficacy of invasive treatment strategies for PLD. In addition, there are no standardized outcome measures to assess treatment success in clinical practice, which hampers the building of an evidence base.

In order to guide physicians on therapy, it is necessary to explore factors involved in the process of treatment decision. To this end, we aimed to delineate patient characteristics and disease-specific factors that trigger therapy. Our secondary aim was to identify determinants that increased the likelihood of a specific invasive therapy for PLD.

## **Materials and methods**

### **Study design and subjects**

We performed a cross-sectional study that included PLD patients coming from two independent PLD registries. Both registries were developed at two nationwide referral hospitals for PLD, Radboud university medical center Nijmegen in the Netherlands (center 1) and University Hospital of Leuven in Belgium (center 2).<sup>(14)</sup> Both hospitals are national referral centers for clinical evaluation and treatment of PLD. The Dutch registry contains all PLD patients who have visited the outpatient clinic of the Department of Hepatology of the Radboud university medical center between January 2008 and February 2015. Patients with ADPKD who had visited the Department of Nephrology between January 2008 and December 2014 were included, if PLD was present. The Belgium registry includes all PLD patients who had visited the outpatient clinic of the Department of Hepatology of the University Hospital of Leuven, from January 2008 to July 2015. According to the Dutch and Belgium regulations, these registries do not need formal ethical approval as this was an observational study.

The inclusion criterium for this analysis was a diagnosis of PLD as documented by patients' physician where diagnosis of PLD had literally to be written down in the medical file of patients, or as shown on radiological imaging by the presence of  $\geq 20$  hepatic cyst larger than 0.5 cm. Underlying diagnosis of ADPKD or ADPLD was a requirement. ADPKD diagnosis was based upon modified Ravine criteria <sup>(15)</sup> and ADPLD diagnosis was based on the

presence of  $\geq 20$  liver cysts, in the absence of renal cysts. If renal cysts were present in patients with ADPLD, the Ravine criteria should not be met. (16) Patients with hepatic cysts due to other diseases (e.g. Caroli's disease, autosomal resistant polycystic kidney disease) were excluded.

### **Potential determinants for treatment**

We selected the following patient characteristics and disease-specific factors as potential determinants for treatment: sex, age at PLD diagnosis, phenotype, underlying diagnosis of PLD (ADPKD or ADPLD), number of symptoms, total liver volume (TLV), height adjusted TLV (hTLV), estrogen use and history of pregnancy. Center was also added as a factor determining choice of treatment. Parameters that pertained treatment decision were chosen on basis of expert opinion, and evidence coming from studies on risk factors for severe PLD. (5, 9-11)

### **Data collection**

Data were retrospectively collected from medical charts of patients. We included information on the following invasive treatment modalities: liver transplantation (combined with or without renal transplantation), resection, fenestration and aspiration sclerotherapy. Experimental therapies such as somatostatin analogues were excluded since these drugs are mainly used in clinical trial settings. We reviewed medical charts for demographics, underlying diagnosis of PLD, age at diagnosis of PLD, TLV, hTLV, estrogen use and pregnancies. We used the most recent value for TLV that was available. Liver volumes had been calculated in the past by 3D measurements of CT scans. This included manually outlining of the liver every 9 mm with interpolation of intermediate slices and calculation of TLV. We also collected data on hepatic cyst phenotype by assessing MRI, CT, ultrasound images or reviewing imaging

reports. We have distinguished between a phenotype with either the presence or absence of one or more dominant cysts ( $\geq 8\text{cm}$ ). Finally, we collected data on the presence of the following symptoms in medical records of patients: abdominal discomfort, feeling full, abdominal pain, tiredness, pain in the rib cage and pain in the side. These symptoms were selected as they were overrepresented in a Dutch population of symptomatic PLD patients.

(17)

### **Statistical analysis**

We performed descriptive statistical analyses to summarize population characteristics. Baseline continuous variables were expressed in mean (standard deviation (SD)) for normally distributed data or median (interquartile range (IQR)) for non-normally distributed data. Dichotomous outcomes were expressed as % (n/n total).

For our primary and secondary aim, we used multivariate logarithmic linked modified Poisson regression analysis to generate risk ratios (RR) for determinants associated with respectively treatment and specific treatment modalities. (18, 19) Risk ratios  $>1$  and  $<1$  were interpreted as respectively increasing and decreasing the likelihood of treatment or a specific therapy, while a risk ratio equal to 1 with a 95% CI smaller than 1 indicates no association. We included a potential determinant in the regression model only if at least 10 patients (1.7% of 578 patients) were exposed to the determinant to guarantee adequate statistical power. For the primary analysis, the dependent variable was specified as treatment or no treatment, whereas treatment was defined as patients who underwent surgical or radiological therapy, at least once. Independent variables included sex, center, age at diagnosis of PLD (defined as age at diagnosis of PLD divided by 10 years), phenotype, underlying diagnosis (ADPKD or ADPLD), number of symptoms, TLV, hTLV, estrogen use and pregnancy in history. We added the variable follow-up, defined as interval from

diagnosis to inclusion in the study divided by 10 years to the model in order to correct for follow-up period.

For our secondary analysis, liver transplantation, resection, fenestration and aspiration sclerotherapy were included as dependent variables. In this analysis, the same independent variables as for the primary analysis were included. Unpaired student's *t*-test or Chi-square test were used to compare patient- or disease characteristics between specific treatment modalities. In addition, a sub-group analysis of hepatic phenotype and treatment strategy between ADPKD and ADPLD patients was performed. Finally, we tested whether patients who underwent aspiration sclerotherapy or fenestration differed on sex, center, age at diagnosis of PLD, phenotype and underlying diagnosis of PLD. If patients underwent aspiration sclerotherapy and fenestration, the first treatment that was given was used for this analysis. A *p*-value of <0.05 was considered statistical significant. Data were analyzed using SPSS 22.0 (SPSS Statistics, Inc., Chicago, IL, U.S.A.).

## Results

### Characterization of the study population

We included 578 patients in our study population and 200 (35%) underwent invasive therapy (Figure 1). The large majority of patients were female (81%) and 383 (66%) had an underlying diagnosis of ADPKD (Table 1). A total of 421 patients showed a phenotype without dominant cysts while a phenotype with concomitant dominant cysts was present in 54 patients. Liver phenotype significantly differed between ADPKD and ADPLD patients (Figure 2). ADPLD patients possessed dominant cysts on radiological imaging in 34 patients (22%) whereas this was the case in only 21 of ADPKD patients (7%) (*p* < 0.001).

Most patients were Dutch (66%, *n*=380) and stratification of patients by center demonstrated that populations from both centers were comparable with respect to sex, TLV and hTLV (Table S1). Dutch patients had more symptoms, were more often diagnosed with ADPLD,



diagnosed at a later age, and more often possessed a phenotype without dominant cysts.

The follow-up of patients at the university hospital of Leuven in Belgium was significantly longer than the follow-up of patients at the Radboudumc in the Netherlands (18 vs. 7 years,  $p < 0.001$ ). Therefore all analysis were corrected for follow-up time by including this in the multivariate model.

### **Determinants that trigger treatment**

Liver transplantation, resection, fenestration and aspiration sclerotherapy were performed in respectively 13%, 1%, 8% and 17% of patients (Figure 1). Multivariate regression analysis revealed that patients who suffer from more symptoms have a 40% higher likelihood (CI: 1.17-1.60,  $p < 0.001$ ) to receive treatment (Figure 3). Every 10 years of diagnosis of PLD was also significantly associated with a 40% increased risk of treatment (CI: 1.04-1.88,  $p = 0.03$ ). TLV, hTLV, estrogen use and pregnancy in history were not included in the regression analyses as data were missing in respectively 56%, 72%, 54% (women only) and 49% (women only) of patients.

### **Characterisation of patient undergoing invasive therapy**

Table S3. provides an overview of patient and disease characteristics of individuals who underwent respectively transplantation, resection, fenestration and aspiration sclerotherapy. Liver transplantation was done at a median age of  $53 \pm 10$  years in a total of 77 patients of whom 69 were diagnosed with ADPKD. In 43% ( $n = 33$ ) of patients this was combined with a renal transplantation and radiological imaging showed a median TLV of 4271 mL [IQR 3438-6243 mL] in these patients. Resection was done in 6 patients (1%) and most patients underwent other treatment modalities as well. Interestingly, a total of 27 patients received >1 different treatment modality. A combination of fenestration and aspiration sclerotherapy was

most common (9%, n=17). Only a small proportion of the total study population underwent fenestration (8%, n=48) and a minority of them had ADPKD (38%, n=18). Patients who underwent fenestration or aspiration sclerotherapy did not significantly differ on sex, diagnosis, age at diagnosis and phenotype (Table S4). We found that the choice for fenestration or aspiration sclerotherapy was mainly center dependent ( $p<0.001$ ). Aspiration sclerotherapy was most frequently performed with a total of 197 procedures in 100 patients. Half of patients (49%, n=97) had > 1 procedure (range 1-15 procedures) and the majority of patients were diagnosed with ADPLD (65%, n=65).

### **Determinants associated with invasive therapies**

We tested the association of six potential determinants with the likelihood to undergo either liver transplantation, fenestration or aspiration sclerotherapy (Figure 3, Table S5).

Determinants associated with hepatic resection were not analyzed as only 7 patients (1%) underwent this procedure and a minimum of 10 patients was required. Patients from center 2 had a 30% higher likelihood ( $p<0.001$ ) to receive a liver transplantation compared to patients from center 1 (Table S5). The likelihood to undergo a liver transplantation increased by 4% with every 10 years of PLD diagnosis (RR 1.035, CI: 1.005-1.065). Multivariate analysis revealed that a diagnosis of ADPLD increased the likelihood to undergo fenestration by 30% ( $p<0.05$ ). The number of symptoms was associated with a higher likelihood to undergo aspiration sclerotherapy (RR 1.1,  $p<0.001$ ). The likelihood to be subjected to aspiration sclerotherapy was center dependent (RR 1.1,  $p=0.03$ ) and increased by follow-up time (RR=1.1,  $P=0.002$ ).

## Therapy differs between ADPKD and ADPLD patients

We subsequently explored whether treatment strategies differed between ADPKD and ADPLD patients. Fenestration and aspiration sclerotherapy were significantly more often performed in ADPLD than in ADPKD patients (15% vs. 5% and 33% vs. 9%, both  $p<0.001$ ) (Figure 4). By contrast, ADPKD patients more frequently underwent liver transplantation (18% vs. 4%,  $p<0.001$ ). In a total of 33 patients undergoing liver transplantation, this was combined with a renal transplantation on the same day.

## Discussion

The results of our large cross-sectional study demonstrate that number of symptoms and age at diagnosis of PLD increased the likelihood to receive treatment for PLD. The choice for either liver transplantation or aspiration sclerotherapy was center-dependent. This underscores a certain arbitrariness, probably due to a lack of evidence that supports any of the available treatment options.

A previous review suggests that the natural course of PLD in ADPLD and ADPKD is similar.

(3) Our study suggests otherwise, and demonstrates that ADPLD patients more often possessed large dominant cysts, a phenotype that is amendable to treatment with fenestration or aspiration sclerotherapy. (3) The available therapies for patients without dominant cysts, most often ADPKD patients, are resection or liver transplantation.(2, 3) A resection is a high risk procedure and not often performed in our population. Liver transplantation is a very invasive procedure, in particular for a disease that does not lead to liver failure or death. In view of a lack of donors, it is not offered widely. (2, 3) These reasons probably explain why only 13% of this severe PLD population was transplanted while a higher percentage is in need of curative therapy. Interestingly, 90% of the transplanted patients were female. This might be explained by a more severe disease course in women,

probably due to the effect of estrogen. (9) However, diagnosis was not significantly associated with any of the invasive therapies. These results are in contradiction with a cohort study showing that aspiration sclerotherapy was significantly more performed in ADPLD patients, while ADPKD patients were more often considered for liver transplantation. (20) About 14% of our treated study population underwent subsequent treatments. The combination of fenestration and aspiration sclerotherapy was the most frequently chosen option. In view of the comparable patients' characteristics, our data lend support to center specific decision making when it comes to the choice between both treatment modalities. These findings indicate that available expertise drives treatment while evidence that singles out the best treatment modality is lacking. A randomized controlled trial comparing effectiveness of fenestration and aspiration sclerotherapy is necessary to find out which treatment strategy is most effective. At the minimum, we should assess treatment outcomes in clinical care of PLD in an uniform fashion. Assessment of TLV, symptoms and health-related quality of life before and after treatment should become standard of care and collected in a registry to build an evidence base of treatment efficacy.(14) In addition, our results demonstrated that liver transplantation was more frequently performed in Belgium while in the Netherlands there was a preference for aspiration sclerotherapy. Due to a different organ donor policy, Belgium has more donors available. This might lower the threshold for physicians to offer transplantation as a treatment option. Our study also discovered that a large proportion of patients received treatment (35%), which is at odds with literature that indicates that only a small subset of patients is symptomatic. (2, 3, 12) Our population consists of patients referred to two nationwide tertiary referral centers, which may have contributed to a selection of a population with more severe disease. This may overestimate the disease burden of PLD in this population as referral to these centers is often triggered by presence of symptoms. The threshold to treat PLD patients is probably lower in tertiary centers because of wider experience with PLD and its treatment options.

The strength of our study was the large, international study population (n=578) in view of the rarity of PLD. In addition, both ADPKD and ADPLD patients were represented in this study as well as the most prevalent surgical therapies. Patients from all over the country are referred to one of both centers and therefore this study provides a good overview of the clinical profile of treated patients in both countries and made it possible to study the effect of center on treatment decision.

The main limitation of our study is the cross-sectional design. We were able to investigate factors involved in treatment decision, but it is impossible to infer causality. The retrospective data collection has led to missing data and therefore liver volume could not be included as potential determinant in our prediction model. Assessment of liver volume is time consuming and trained staff and software is required. This might explain the amount of missing data for TLV. Although, it is questionable whether liver volume plays a major role in the treatment decision process as so little volumes were available in the medical charts. Therefore this probably had no major impact on the primary outcome. This registry will continue in a prospective fashion including more patients worldwide with a long-term follow up. A prospective nature will decrease the number of missing data and the long-term follow-up will support to learn more about the prognosis of PLD.

## **Conclusion**

The results of our international cross-sectional study suggests that a higher number of symptoms and every 10 years of PLD diagnosis increases the likelihood to undergo treatment by 40%. The choice to elect a particular modality is center dependent. The major implication of these findings is that physicians should bear in mind that there is no evidence that favors either treatment option, and this contributes to center specific preferences.

Therefore, assessing efficacy of therapy by measuring liver volume and symptom burden, are essential to gain evidence among the best treatment option. Future studies comparing

efficacy of treatment modalities would be helpful to fill the gap of knowledge among the best treatment option.

## References

1. Cnossen WR, Te Morsche RH, Hoischen A, Gilissen C, Venselaar H, Mehdi S, et al. LRP5 variants may contribute to ADPKD. *European journal of human genetics* : EJHG. 2015.
2. Drenth JP, Chrispijn M, Nagorney DM, Kamath PS, Torres VE. Medical and surgical treatment options for polycystic liver disease. *Hepatology*. 2010;52(6):2223-30.
3. Gevers TJ, Drenth JP. Diagnosis and management of polycystic liver disease. *Nat Rev Gastroenterol Hepatol*. 2013;10(2):101-8.
4. Bae KT, Zhu F, Chapman AB, Torres VE, Grantham JJ, Guay-Woodford LM, et al. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. *Clinical journal of the American Society of Nephrology* : CJASN. 2006;1(1):64-9.
5. Van Keimpema L, De Koning DB, Van Hoek B, Van Den Berg AP, Van Oijen MG, De Man RA, et al. Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. *Liver international : official journal of the International Association for the Study of the Liver*. 2011;31(1):92-8.
6. Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. *Kidney Int*. 2009;76(2):149-68.
7. Wijnands TF, Neijenhuis MK, Kievit W, Nevens F, Hogan MC, Torres VE, et al. Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume. *Liver Int*. 2014;34(10):1578-83.
8. Arnold HL, Harrison SA. New advances in evaluation and management of patients with polycystic liver disease. *Am J Gastroenterol*. 2005;100(11):2569-82.
9. Sherstha R, McKinley C, Russ P, Scherzinger A, Bronner T, Showalter R, et al. Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease. *Hepatology*. 1997;26(5):1282-6.
10. D'Agnolo HM, Drenth JP. Risk factors for progressive polycystic liver disease: where do we stand? *Nephrol Dial Transplant*. 2015.
11. Bae KT, Zhu F, Chapman AB, Torres VE, Grantham JJ, Guay-Woodford LM, et al. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. *Clin J Am Soc Nephrol*. 2006;1(1):64-9.
12. Abu-Wasel B, Walsh C, Keough V, Molinari M. Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases. *World J Gastroenterol*. 2013;19(35):5775-86.
13. Savige J, Mallett A, Tunnicliffe DJ, Rangan GK. KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of Polycystic Liver Disease. *Seminars in nephrology*. 2015;35(6):618-22 e5.
14. D'Agnolo HM, Kievit W, Andrade RJ, Karlsen TH, Wedemeyer H, Drenth JP. Creating an effective clinical registry for rare diseases. *United Eur Gastroent J*. 2015.
15. Pei Y, Obaji J, Dupuis A, Paterson AD, Magistroni R, Dicks E, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. *J Am Soc Nephrol*. 2009;20(1):205-12.
16. Karhunen PJ, Tenhu M. Adult polycystic liver and kidney diseases are separate entities. *Clin Genet*. 1986;30(1):29-37.

17. Neijenhuis MK, Gevers TJ, Hogan MC, Kamath PS, Wijnands TF, van den Ouweland RCPM, et al. Development and Validation of a Disease-Specific Questionnaire to Assess Patient-Reported Symptoms in Polycystic Liver Disease. *Hepatology*. 2016.
18. Zou G. A modified poisson regression approach to prospective studies with binary data. *Am J Epidemiol*. 2004;159(7):702-6.
19. Knol MJ, Le Cessie S, Algra A, Vandenbroucke JP, Groenwold RH. Overestimation of risk ratios by odds ratios in trials and cohort studies: alternatives to logistic regression. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*. 2012;184(8):895-9.
20. Hoevenaren IA, Wester R, Schrier RW, McFann K, Doctor RB, Drenth JP, et al. Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease. *Liver Int*. 2008;28(2):264-70.

## Figure legends

**Figure 1. Overview of the study population.** A total of 578 patients were included and 35% (n=200) received therapy. A number of patients received  $\geq 1$  treatment modality.

**Figure 2. Liver cyst phenotype in ADPKD and ADPLD patients. (A)** A phenotype with dominant cysts ( $\geq 8$  cm) was significantly more present in ADPLD patients compared to ADPKD patients (22% vs. 7%,  $p < 0.001$ ). **(B)** A phenotype without dominant cysts was more often present in ADPKD (93% vs. 78%,  $p < 0.001$ ).

**Figure 3. Forest plots showing risk ratios with 95% confidence intervals for respectively treatment in general, liver transplantation, fenestration and aspiration sclerotherapy.** Risk ratios were calculated by multivariate regression analyses. A risk ratio of  $< 1$  represents a decreased risk and  $> 1$  increased risk for treatment. A risk ratio of 1 (dotted line) indicates no association.

**Figure 4. Treatment strategies for PLD in autosomal dominant polycystic kidney disease (ADPKD) and autosomal dominant polycystic liver disease (ADPLD).** Liver transplantation was more often done in ADPKD patients whereas fenestration and aspiration sclerotherapy favored ADPLD patients.

## Tables

**Table 1. Characteristics of the study population**

	<b>Complete population (n=578)</b>	
Female	468	81%
ADPKD	383	66%
Age diagnosis PLD	45	±13
Center 1	380	66%
<b>Volumetry*</b>		
TLV (mL)	4093	[2717-6066]
hTLV (mL/m)	2639	[1669-3840]
<b>Phenotype*</b>		
≥ 20 cysts + ≥1 dominant cyst	54	11%
≥ 20 cysts	421	89%
<b>Symptoms</b>		
Abdominal tension	225	39%
Feeling full	210	36%
Abdominal pain	141	24%
Tiredness	129	22%
Pain rib cage	120	21%
Pain side	78	14%
No of symptoms	1	[1-3]

Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; hTLV, height adjusted total liver volume; PLD, polycystic liver disease; TLV, total liver volume.

Data are in number and percentage (%), mean ± standard deviation, or median and interquartile range [IQR].

Center 1= Radboud university medical center Nijmegen, the Netherlands, center 2= University Hospital of Leuven, Belgium

\*Data were missing in respectively 56%, 72% and 18% of patients for TLV, hTLV and phenotype






Figure 1.




Figure 2.




Figure 3.




Figure 4.